Bollard Group’s iShares Biotechnology ETF IBB Stock Holding History

Bollard Group’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$56K	Hold	334	–	–	﹤0.01%	234
2025 Q4	$56K	Hold	334	–	–	﹤0.01%	227
2025 Q3	$48K	Hold	334	–	–	﹤0.01%	209
2025 Q2	$42K	Hold	334	–	–	﹤0.01%	231
2025 Q1	$43K	Hold	334	–	–	﹤0.01%	222
2024 Q4	$44K	Hold	334	–	–	﹤0.01%	224
2024 Q3	$49K	Hold	334	–	–	﹤0.01%	235
2024 Q2	$46K	Hold	334	–	–	﹤0.01%	235
2024 Q1	$46K	Hold	334	–	–	﹤0.01%	226
2023 Q4	$45K	Hold	334	–	–	﹤0.01%	224
2023 Q3	$41K	Hold	334	–	–	﹤0.01%	222
2023 Q2	$42K	Hold	334	–	–	﹤0.01%	228
2023 Q1	$43K	Hold	334	–	–	﹤0.01%	225
2022 Q4	$44K	Buy	334 +1	+0.3%	+$129	﹤0.01%	215
2022 Q3	$39K	Sell	333 -547	-62%	-$67.9K	﹤0.01%	221
2022 Q2	$104K	Hold	880	–	–	﹤0.01%	200
2022 Q1	$115K	Buy	880 +1	+0.1%	+$130	﹤0.01%	278
2021 Q4	$134K	Hold	879	–	–	﹤0.01%	268
2021 Q3	$142K	Hold	879	–	–	﹤0.01%	258
2021 Q2	$144K	Hold	879	–	–	﹤0.01%	249
2021 Q1	$132K	Buy	879 +1	+0.1%	+$159	﹤0.01%	250
2020 Q4	$133K	Sell	878 -303	-26%	-$43.3K	0.01%	237
2020 Q3	$160K	Hold	1,181	–	–	0.01%	210
2020 Q2	$161K	Hold	1,181	–	–	0.01%	201
2020 Q1	$127K	Hold	1,181	–	–	0.01%	157
2019 Q4	$142K	Buy	1,181 +1	+0.1%	+$112	﹤0.01%	167
2019 Q3	$117K	Buy	1,180 +1	+0.1%	+$105	﹤0.01%	172
2019 Q2	$129K	Buy	1,179 +1	+0.1%	+$106	﹤0.01%	185
2019 Q1	$132K	Hold	1,178	–	–	0.01%	185
2018 Q4	$114K	Hold	1,178	–	–	0.01%	183
2018 Q3	$144K	Buy	1,178 +2	+0.2%	+$236	0.01%	187
2018 Q2	$129K	Hold	1,176	–	–	0.01%	185
2018 Q1	$126K	Hold	1,176	–	–	0.01%	186
2017 Q4	$126K	Hold	1,176	–	–	0.01%	181
2017 Q3	$131K	Hold	1,176	–	–	0.01%	185
2017 Q2	$121K	Buy	1,176 +3	+0.3%	+$295	0.01%	195
2017 Q1	$115K	Hold	1,173	–	–	0.01%	201
2016 Q4	$104K	Sell	1,173 -75	-6%	-$6.83K	0.01%	202
2016 Q3	$120K	Buy	1,248 +633	+103%	+$60.2K	0.01%	195
2016 Q2	$53K	Hold	615	–	–	﹤0.01%	207
2016 Q1	$54K	Hold	615	–	–	﹤0.01%	208
2015 Q4	$69K	Hold	615	–	–	0.01%	209
2015 Q3	$62K	Hold	615	–	–	0.01%	225
2015 Q2	$76K	Hold	615	–	–	0.01%	220
2015 Q1	$70K	Hold	615	–	–	0.01%	221
2014 Q4	$62K	Sell	615 -28,473	-98%	-$2.77M	0.01%	220
2014 Q3	$2.65M	Buy	29,088 +615	+2%	+$54K	0.25%	63
2014 Q2	$2.44M	Hold	28,473	–	–	0.24%	62
2014 Q1	$2.24M	Hold	28,473	–	–	0.23%	59
2013 Q4	$2.15M	Hold	28,473	–	–	0.24%	60
2013 Q3	$1.99M	Buy	+28,473	New	+$1.87M	0.23%	57

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bollard Group's IBB Position: Q1 2026 in Review

Bollard Group held its iShares Biotechnology ETF (IBB) position steady in Q1 2026 at 334 shares worth $56K. The position accounts for ﹤0.01% of the portfolio, ranked #234.

Bollard Group first reported a position in IBB in Q3 2013 and has held it in 51 quarters since. The position peaked at $2.65M in Q3 2014. 919 funds tracked by Wall St. Rank hold IBB as of Q1 2026.

Bollard Group held 334 shares of iShares Biotechnology ETF worth $56K as of Q1 2026.
Bollard Group left its iShares Biotechnology ETF share count unchanged in Q1 2026.
iShares Biotechnology ETF made up ﹤0.01% of Bollard Group's portfolio in Q1 2026, its #234 holding.
Bollard Group first reported a position in iShares Biotechnology ETF in Q3 2013 and has held it in 51 quarters since.
Bollard Group's iShares Biotechnology ETF position peaked at $2.65M in Q3 2014.
919 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2026.

Based on Bollard Group's 13F filing for Q1 2026, filed 14 May 2026.